Search Results - "CHENG-DER YU"

  • Showing 1 - 15 results of 15
Refine Results
  1. 1
  2. 2

    Design and synthesis of glyco-peptides as anti-cancer agents targeting thrombin-protease activated receptor-1 interaction by Chang, Yu-Hsuan, Wu, Jen-Chine, Yu, Hui-Ming, Hsu, Hua-Ting, Wu, Ying-Ta, Yu, Alice Lin-Tsing, Yu, Cheng-Der Tony, Wong, Chi-Huey

    “…Thrombin activates protease-activated receptor-1 (PAR-1) through binding to exosite I and the active site to promote tumor growth. We have developed a new…”
    Get more information
    Journal Article
  3. 3

    Preclinical Studies of OBI-999: A Novel Globo H-Targeting Antibody-Drug Conjugate by Yang, Ming-Chen, Shia, Chi-Sheng, Li, Wan-Fen, Wang, Chun-Chung, Chen, I-Ju, Huang, Teng-Yi, Chen, Yu-Jung, Chang, Hui-Wen, Lu, Chi-Huan, Wu, Yueh-Chin, Wang, Nan-Hsuan, Lai, Jiann-Shiun, Yu, Cheng-Der, Lai, Ming-Tain

    Published in Molecular cancer therapeutics (01-06-2021)
    “…Globo H (GH), a hexasaccharide, is expressed at low levels in normal tissues but is highly expressed in multiple cancer types, rendering it a promising target…”
    Get full text
    Journal Article
  4. 4

    Abstract 4815: Novel Globo H targeting antibody-drug conjugate with binding specificity and anti-tumor efficacy in multiple cancer types by Yang, Ming-Chen, Chen, Yu-Jung, Shia, Chi-Sheng, Chang, Hui-Wen, Li, Wan-Fen, Yu, Cheng-Der Tony, Chen, I-Ju

    Published in Cancer research (Chicago, Ill.) (01-07-2019)
    “…Abstract Background: Globo H, a hexasaccharide, has been reported to be highly expressed in multiple cancers types, but not express or, if at all, express to a…”
    Get full text
    Journal Article
  5. 5
  6. 6
  7. 7

    Transforming growth factor-α (TGF-α) in a semisolid dosage form : preservative and vehicle selection by TAN, E. L, SHAH, H. S, LEISTER, K. J, KOZICK, L. M, PASCIAK, P, VANDERLAAN, R. K, CHENG-DER YU, PATEL, B

    Published in Pharmaceutical research (01-08-1993)
    “…The selection of an ideal semisolid vehicle for growth factors presents a challenge. Some antimicrobial agents are known to delay wound healing. The objective…”
    Get full text
    Journal Article
  8. 8

    Cascade impactor method for the droplet size characterization of a metered-dose nasal spray by Yu, C D, Jones, R E, Henesian, M

    Published in Journal of pharmaceutical sciences (01-03-1984)
    “…A relatively rapid and simple method was developed to characterize the droplet size of a metered-dose nasal spray. The study primarily concerned the…”
    Get more information
    Journal Article
  9. 9

    Physical model evaluation of topical prodrug delivery--simultaneous transport and bioconversion of vidarabine-5'-valerate IV: Distribution of esterase and deaminase enzymes in hairless mouse skin by Yu, C D, Fox, J L, Higuchi, W I, Ho, N F

    Published in Journal of pharmaceutical sciences (01-07-1980)
    “…A semiquantitative assessment of estrase and deaminase distributions in hairless mouse skin was performed in vitro. The enzyme activities were quantified using…”
    Get more information
    Journal Article
  10. 10

    Physical model evaluation of topical prodrug delivery--simultaneous transport and bioconversion of vidarabine-5'-valerate V: Mechanistic analysis of influence of nonhomogeneous enzyme distributions in hairless mouse skin by Yu, C D, Gordon, N A, Fox, J L, Higuchi, W I, Ho, N F

    Published in Journal of pharmaceutical sciences (01-07-1980)
    “…The mathematical problem of simultaneous transport and metabolism in the case of nonuniform enzyme distributions in the skin was solved, and the solutions were…”
    Get more information
    Journal Article
  11. 11

    Physical model evaluation of topical prodrug delivery--simultaneous transport and bioconversion of vidarabine-5'-valerate III: Permeability differences of vidarabine and n-pentanol in components of hairless mouse skin by Yu, C D, Higuchi, W I, Ho, N F, Fox, J L, Flynn, G L

    Published in Journal of pharmaceutical sciences (01-07-1980)
    “…The permeation behavior of 3H-vidarabine (3H-9-beta-D-ara-binofuranosyladenine) and 14C-n-pentanol through different strata of hairless mouse skin was studied…”
    Get more information
    Journal Article
  12. 12
  13. 13

    Physical model evaluation of topical prodrug delivery-simultaneous transport and bioconversion of vidarabine-5'-valerate I: Physical model development by Yu, C D, Fox, J L, Ho, N F, Higuchi, W I

    Published in Journal of pharmaceutical sciences (01-11-1979)
    “…A physical model approach to the topical delivery of a vidarabine ester prodrug was investigated. It involved modeling, theoretical simulations, experimental…”
    Get more information
    Journal Article
  14. 14

    Endemic Burkholderia cepacia Bacteraemia: Clinical Features and Antimicrobial Susceptibilities of Isolates by YU, W.-L, WANG, D.-Y, LIN, C.-W, TSOU, M.-F

    “…Burkholderia cepacia has emerged as a nosocomial pathogen, causing numerous outbreaks, particularly among cystic fibrosis (CF) patients. Reports of clinical…”
    Get full text
    Journal Article
  15. 15